These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 23610445)
1. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Satoh H; Moriguchi T; Takai J; Ebina M; Yamamoto M Cancer Res; 2013 Jul; 73(13):4158-68. PubMed ID: 23610445 [TBL] [Abstract][Full Text] [Related]
2. NRF2 Intensifies Host Defense Systems to Prevent Lung Carcinogenesis, but After Tumor Initiation Accelerates Malignant Cell Growth. Satoh H; Moriguchi T; Saigusa D; Baird L; Yu L; Rokutan H; Igarashi K; Ebina M; Shibata T; Yamamoto M Cancer Res; 2016 May; 76(10):3088-96. PubMed ID: 27020858 [TBL] [Abstract][Full Text] [Related]
3. Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway. Shibata T; Saito S; Kokubu A; Suzuki T; Yamamoto M; Hirohashi S Cancer Res; 2010 Nov; 70(22):9095-105. PubMed ID: 21062981 [TBL] [Abstract][Full Text] [Related]
4. The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer. Tao S; Rojo de la Vega M; Chapman E; Ooi A; Zhang DD Mol Carcinog; 2018 Feb; 57(2):182-192. PubMed ID: 28976703 [TBL] [Abstract][Full Text] [Related]
5. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157 [TBL] [Abstract][Full Text] [Related]
6. Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors. Hayashi M; Kuga A; Suzuki M; Panda H; Kitamura H; Motohashi H; Yamamoto M Cancer Res; 2020 Aug; 80(16):3331-3344. PubMed ID: 32636316 [TBL] [Abstract][Full Text] [Related]
7. Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression. Cicchini M; Buza EL; Sagal KM; Gudiel AA; Durham AC; Feldser DM Cell Rep; 2017 Feb; 18(8):1958-1969. PubMed ID: 28228261 [TBL] [Abstract][Full Text] [Related]
12. [Redox-dependent signaling system Nrf2/are in inflammation]. Men'shikova EB; Tkachev VO; Zenkov NK Mol Biol (Mosk); 2010; 44(3):389-404. PubMed ID: 20608163 [TBL] [Abstract][Full Text] [Related]
13. Nrf2 and antioxidant defense against CYP2E1 toxicity. Cederbaum A Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1223-44. PubMed ID: 19671018 [TBL] [Abstract][Full Text] [Related]
14. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma. Cho HC; Lai CY; Shao LE; Yu J Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965 [TBL] [Abstract][Full Text] [Related]
15. Nrf2-activated expression of sulfiredoxin contributes to urethane-induced lung tumorigenesis. Mishra M; Jiang H; Chawsheen HA; Gerard M; Toledano MB; Wei Q Cancer Lett; 2018 Sep; 432():216-226. PubMed ID: 29906488 [TBL] [Abstract][Full Text] [Related]
16. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma. Yeddula N; Xia Y; Ke E; Beumer J; Verma IM Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681 [TBL] [Abstract][Full Text] [Related]
17. Genomic landscape of chemical-induced lung tumors under Nrf2 different expression levels. Satoh H; Arai Y; Furukawa E; Moriguchi T; Hama N; Urushidate T; Totoki Y; Kato M; Ohe Y; Yamamoto M; Shibata T Carcinogenesis; 2022 Aug; 43(7):613-623. PubMed ID: 35561328 [TBL] [Abstract][Full Text] [Related]
18. Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis. Iida K; Itoh K; Maher JM; Kumagai Y; Oyasu R; Mori Y; Shimazui T; Akaza H; Yamamoto M Carcinogenesis; 2007 Nov; 28(11):2398-403. PubMed ID: 17602169 [TBL] [Abstract][Full Text] [Related]
19. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767 [TBL] [Abstract][Full Text] [Related]
20. Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Horio Y; Chen A; Rice P; Roth JA; Malkinson AM; Schrump DS Mol Carcinog; 1996 Dec; 17(4):217-23. PubMed ID: 8989915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]